FindTrial
Sign In

Efficacy and safety of liposomal bupivacaine for stellate ganglion block in preventing postoperative new-onset atrial fibrillation in patients undergoing off-pump coronary artery bypass grafting: A randomized, double-blind, controlled trial

Efficacy and safety of liposomal bupivacaine for stellate ganglion block in preventing postoperative new-onset atrial fibrillation in patients undergoing off-pump coronary artery bypass grafting: A randomized, double-blind, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124698
Enrollment
Unknown
Registered
2026-05-15
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative new-onset atrial fibrillation

Interventions

Control group:Ultrasound scanning of the left cervical region
Intervention group:Ultrasound-guided left stellate ganglion block( liposomal bupivacaine,0.25% 10ml)

Sponsors

General Hospital of Northern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective isolated off-pump coronary artery bypass grafting (OPCABG), without gender restriction; 2.Aged 18–70 years, with a body mass index (BMI) of 18–30 kg/m^2; 3.American Society of Anesthesiologists (ASA) physical status class III or IV; 4. Willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. History of atrial fibrillation; 2.New York Heart Association (NYHA) functional class IV, or left ventricular ejection fraction (LVEF) 25%); severe mitral valve disease (mitral valve area 4 cm^2); 8.Moderate to severe hepatic impairment, or concurrent use (including within 2 weeks of discontinuation) of hepatic enzyme inducers or inhibitors; 9.Decompensated renal dysfunction or renal failure (serum creatinine > 177 µmol/L); 10. Severe disturbance of consciousness, or presence of psychiatric disorders (schizophrenia, mania, bipolar disorder, psychosis, etc.) or cognitive dysfunction; 11. Use of class I or III antiarrhythmic drugs before surgery; 12.Diseases requiring radiotherapy, chemotherapy, or long-term corticosteroid therapy; 13. Poorly controlled thyroid function; 14. Participation in another clinical trial.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative atrial fibrillation within 7 days after OPCAB;—

Secondary

MeasureTime frame
AF burden;Maximum heart rate during AF;Maximum AF episode duration;Heart rate variability parameters;Plasma inflammatory markers;Antiarrhythmic therapy status;Patient clinical outcomes;—

Countries

China

Contacts

Public ContactTian Xiao

General Hospital of Northern Theater Command

358656865@qq.com+86 158 4038 6546

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026